Talk to your healthcare provider before starting HEMLIBRA®
Together, you can create a plan that works for you. Here are some important topics to review with your healthcare provider.
Your healthcare provider will teach you how to inject HEMLIBRA. They
can also let you know what supplies you will need. Ask your healthcare
provider for suggestions or tips on how to stick with your new
- HEMLIBRA is not a cure for hemophilia
- HEMLIBRA is for routine prophylactic use only. It should not be used in emergencies to treat a bleed (on-demand therapy)
- You can get a bleed while taking HEMLIBRA. You and your healthcare provider should create a plan on when and how to treat or manage a bleed
- HEMLIBRA increases the potential for your blood to clot. Carefully follow your healthcare provider’s instructions regarding when to use an on-demand bypassing agent or factor VIII (FVIII) and the recommended dose and schedule to use for breakthrough bleed treatment
- If aPCC (Feiba®) is needed, talk to your healthcare provider in case you feel you need more than 100 U/kg of aPCC (Feiba®) total
- If you have hemophilia A without FVIII (factor VIII) inhibitors, you can use your factor VIII as recommended by your doctor
Being ready for an emergency situation is important. Consider updating your emergency medical information. It helps to know what to do if a trip to the emergency room (ER) is necessary.
- Medical alert bracelets and wallet or phone cards are common ways to keep information handy during an emergency. Download our ER card here
- Many smartphones have a “health” or “medical ID” function that allows important information to be accessed in an emergency without a password
- You may also want to talk to your healthcare provider about a travel letter. This provides information about your condition, medications taken, and supplies you need to carry
HEMLIBRA may cause serious side effects when used with activated prothrombin complex concentrate (aPCC; Feiba®), including thrombotic microangiopathy (TMA), and blood clots (thrombotic events). If aPCC (Feiba®) is needed, talk to your healthcare provider in case you feel you need more than 100 U/kg of aPCC (Feiba®) total.
Some lab tests that measure how well your blood is clotting may be impacted by HEMLIBRA. This could cause incorrect test results. Ask what information you should share with a healthcare provider prior to a medical procedure (eg, surgery, dental cleaning).
- ADAs are our body’s natural reaction to medicines that seem foreign
- ADAs are not FVIII inhibitors and do not impact factor VIII replacement therapy or other medicines
- Some ADAs have the potential to neutralize HEMLIBRA, making it less effective. Be sure to speak with your healthcare provider if you have questions about ADAs
The incidence of ADAs in clinical trials was 3.5%, with <1% ADAs with neutralizing potential. There was no apparent impact of the presence of ADAs on safety. The number of patients with HEMLIBRA-related ADAs may be underreported due to the sensitivity of the test used to detect them.
Use HEMLIBRA exactly as it’s prescribed.
While medicines are sometimes prescribed for some reasons not listed in the Medication Guide, do not use HEMLIBRA for a condition for which it was not prescribed. Do not give HEMLIBRA to other people, even if they have the same symptoms that you have. It may harm them. You can ask your pharmacist or healthcare provider for more information about HEMLIBRA.